Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#2163 Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Carcinomas: Case Series

Introduction: High-grade neuroendocrine carcinomas (NECs) possess inevitable tendencies to metastasise and hold poor prospects of survival. Patients with neuroendocrine tumours who progress after medical management can be treated with peptide receptor radionuclide therapy (PRRT), on the proviso that there is positive uptake on 68Ga-DOTATATE PET/CT imaging. Despite this, a proportion of patients who exhibit positive imaging respond poorly to therapy. Management of NECs is currently limited; evidence for treating NECs with PRRT is scarce.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Butt S, Evans J, Sharma R,

Keywords: neuroendocrine, carcinoma, tumours, PRRT,

#457 Comparison of Transarterial Liver-Directed Therapies (LDT) for Low-Grade Metastatic Neuroendocrine Tumors (mNETs)

Introduction: Transarterial LDT can ameliorate symptoms and improve time to tumor progression (TTP) in mNETs.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Engelman E, Leon-Ferre R, Naraev B, Sharma N, Sun S,

Keywords: hepatic, artery, embolization, chemoembolization, radioembolization, neuroendocrine, tumors,

#439 Chromogranin A (CgA) and Pancreastatin (PcSt) as Predictors of Peptide Receptor Radionuclide Therapy (PRRT) Outcomes in Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)

Introduction: CgA and PcSt are widely used in assessing response to treatment in mNETs.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Sharma N, Naraev B, Engelman E, Zimmerman M, Bushnell D,

Keywords: pancreastatin, chromogranin, peptide, receptor, radionuclide, therapy, PRRT, neuroendocrine, tumors,

#402 Single-Center Treatment Outcomes in Patients (pts) with High Grade Neuroendocrine Carcinoma of the Uterine Cervix (cNEC)

Introduction: cNEC is a rare and aggressive cancer; the best treatment is unknown.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Naraev B, Sharma N, Goodheart M, O'Dorisio T, Halfdanarson T,

Keywords: neuroendocrine, carcinoma, cervix, outcomes,

#395 Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) in North American Cohort of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)

Introduction: PRRT is an accepted treatment in Europe for patients (pts) with mNETs, but considered investigational in the USA.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Naraev B, Sharma N, Engelman E, Bushnell D, O'Dorisio T,

Keywords: peptide, receptor, radionuclide, therapy, PRRT, neuroendocrine, tumors,